PURPOSE: Pazopanib, an oral multikinase angiogenesis inhibitor, prolongs progression-free survival in adults with soft tissue sarcoma (STS). A phase I pharmacokinetic and pharmacodynamic study of two formulations of pazopanib was performed in children with STS or other refractory solid tumors. PATIENTS AND METHODS: Pazopanib (tablet formulation) was administered once daily in 28-day cycles at four dose levels (275 to 600 mg/m(2)) using the rolling-six design. Dose determination for a powder suspension was initiated at 50% of the maximum-tolerated dose (MTD) for the intact tablet. Ten patients with STS underwent dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) scanning at baseline and 15 ± 2 days after initiation of pazopanib at the tablet MTD. RESULTS: Fifty-three patients were enrolled; 51 were eligible (26 males; median age, 12.9 years; range, 3.8 to 23.9 years). Hematologic and nonhematologic toxicities were generally mild, with dose-limiting lipase, amylase, and ALT elevation, proteinuria, and hypertension. One patient with occult brain metastasis had grade 4 intracranial hemorrhage. The MTD was 450 mg/m(2) for tablet and 160 mg/m(2) for suspension. Steady-state trough concentrations were reached by day 15 and did not seem to be dose dependent. One patient each with hepatoblastoma or desmoplastic small round cell tumor achieved a partial response; eight patients had stable disease for ≥ six cycles, seven of whom had sarcoma. All patients with evaluable DCE-MRI (n = 8) experienced decreases in tumor blood volume and permeability (P < .01). Placental growth factor increased, whereas endoglin and soluble vascular endothelial growth factor receptor-2 decreased (P < .01; n = 41). CONCLUSION: Pazopanib is well tolerated in children, with evidence of antiangiogenic effect and potential clinical benefit in pediatric sarcoma.
PURPOSE:Pazopanib, an oral multikinase angiogenesis inhibitor, prolongs progression-free survival in adults with soft tissue sarcoma (STS). A phase I pharmacokinetic and pharmacodynamic study of two formulations of pazopanib was performed in children with STS or other refractory solid tumors. PATIENTS AND METHODS: Pazopanib (tablet formulation) was administered once daily in 28-day cycles at four dose levels (275 to 600 mg/m(2)) using the rolling-six design. Dose determination for a powder suspension was initiated at 50% of the maximum-tolerated dose (MTD) for the intact tablet. Ten patients with STS underwent dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) scanning at baseline and 15 ± 2 days after initiation of pazopanib at the tablet MTD. RESULTS: Fifty-three patients were enrolled; 51 were eligible (26 males; median age, 12.9 years; range, 3.8 to 23.9 years). Hematologic and nonhematologic toxicities were generally mild, with dose-limiting lipase, amylase, and ALT elevation, proteinuria, and hypertension. One patient with occult brain metastasis had grade 4 intracranial hemorrhage. The MTD was 450 mg/m(2) for tablet and 160 mg/m(2) for suspension. Steady-state trough concentrations were reached by day 15 and did not seem to be dose dependent. One patient each with hepatoblastoma or desmoplastic small round cell tumor achieved a partial response; eight patients had stable disease for ≥ six cycles, seven of whom had sarcoma. All patients with evaluable DCE-MRI (n = 8) experienced decreases in tumor blood volume and permeability (P < .01). Placental growth factor increased, whereas endoglin and soluble vascular endothelial growth factor receptor-2 decreased (P < .01; n = 41). CONCLUSION:Pazopanib is well tolerated in children, with evidence of antiangiogenic effect and potential clinical benefit in pediatric sarcoma.
Authors: Petros G Nikolinakos; Nasser Altorki; David Yankelevitz; Hai T Tran; Shaoyu Yan; Dilip Rajagopalan; Walter Bordogna; Lone H Ottesen; John V Heymach Journal: Cancer Res Date: 2010-03-09 Impact factor: 12.701
Authors: E I Heath; E G Chiorean; C J Sweeney; J P Hodge; J J Lager; K Forman; L Malburg; T Arumugham; M M Dar; A B Suttle; S D Gainer; P LoRusso Journal: Clin Pharmacol Ther Date: 2010-10-27 Impact factor: 6.875
Authors: B C Goh; N J Reddy; U B Dandamudi; K H Laubscher; T Peckham; J P Hodge; A B Suttle; T Arumugham; Y Xu; C-F Xu; J Lager; M M Dar; L D Lewis Journal: Clin Pharmacol Ther Date: 2010-09-29 Impact factor: 6.875
Authors: Elizabeth Fox; Richard Aplenc; Rochelle Bagatell; Meredith K Chuk; Eva Dombi; Wendy Goodspeed; Anne Goodwin; Marie Kromplewski; Nalini Jayaprakash; Marcelo Marotti; Kathryn H Brown; Barbara Wenrich; Peter C Adamson; Brigitte C Widemann; Frank M Balis Journal: J Clin Oncol Date: 2010-11-08 Impact factor: 44.544
Authors: M Scartozzi; E Galizia; S Chiorrini; R Giampieri; R Berardi; C Pierantoni; S Cascinu Journal: Ann Oncol Date: 2008-10-07 Impact factor: 32.976
Authors: Herbert I Hurwitz; Afshin Dowlati; Shermini Saini; Shawna Savage; A Benjamin Suttle; Diana M Gibson; Jeffrey P Hodge; Elmar M Merkle; Lini Pandite Journal: Clin Cancer Res Date: 2009-06-09 Impact factor: 12.531
Authors: Cora N Sternberg; Ian D Davis; Jozef Mardiak; Cezary Szczylik; Eunsik Lee; John Wagstaff; Carlos H Barrios; Pamela Salman; Oleg A Gladkov; Alexander Kavina; Juan J Zarbá; Mei Chen; Lauren McCann; Lini Pandite; Debasish F Roychowdhury; Robert E Hawkins Journal: J Clin Oncol Date: 2010-01-25 Impact factor: 44.544
Authors: Alberto Broniscer; Justin N Baker; Michael Tagen; Arzu Onar-Thomas; Richard J Gilbertson; Andrew M Davidoff; Atmaram S Pai Panandiker; Atmaram Pai Panandiker; Wing Leung; Thomas K Chin; Clinton F Stewart; Mehmet Kocak; Christopher Rowland; Thomas E Merchant; Sue C Kaste; Amar Gajjar Journal: J Clin Oncol Date: 2010-10-04 Impact factor: 44.544
Authors: Viswanath Reddy Belum; Courtney Washington; Christine A Pratilas; Vincent Sibaud; Franck Boralevi; Mario E Lacouture Journal: Pediatr Blood Cancer Date: 2015-02-12 Impact factor: 3.167
Authors: Lucas Moreno; Andrew D J Pearson; Xavier Paoletti; Irene Jimenez; Birgit Geoerger; Pamela R Kearns; C Michel Zwaan; Francois Doz; Andre Baruchel; Josef Vormoor; Michela Casanova; Stefan M Pfister; Bruce Morland; Gilles Vassal Journal: Nat Rev Clin Oncol Date: 2017-05-16 Impact factor: 66.675
Authors: Stephan D Voss; Julia Glade-Bender; Sheri L Spunt; Steven G DuBois; Brigitte C Widemann; Julie R Park; Sarah E S Leary; Marvin D Nelson; Peter C Adamson; Susan M Blaney; Brenda Weigel Journal: Pediatr Blood Cancer Date: 2014-09-24 Impact factor: 3.167
Authors: Sarah E S Leary; Julie R Park; Joel M Reid; Andrew T Ralya; Sylvain Baruchel; Bing Wu; Timothy P L Roberts; Xiaowei Liu; Charles G Minard; Elizabeth Fox; Brenda Weigel; Susan Blaney Journal: Clin Cancer Res Date: 2017-07-27 Impact factor: 12.531
Authors: Rajen J Mody; John R Prensner; Jessica Everett; D Williams Parsons; Arul M Chinnaiyan Journal: Pediatr Blood Cancer Date: 2016-10-17 Impact factor: 3.167
Authors: Vivek Subbiah; Salah-Eddine Lamhamedi-Cherradi; Branko Cuglievan; Brian A Menegaz; Pamela Camacho; Winston Huh; Vandhana Ramamoorthy; Pete M Anderson; Raphael E Pollock; Dina C Lev; Wei Qiao; Mary Frances McAleer; Robert S Benjamin; Shreyaskumar Patel; Cynthia E Herzog; Najat C Daw; Barry W Feig; Alexander J Lazar; Andrea Hayes-Jordan; Joseph A Ludwig Journal: Clin Cancer Res Date: 2018-06-05 Impact factor: 12.531
Authors: Aaron R Weiss; Brandon Hayes-Lattin; Matthew A Kutny; Wendy Stock; Kristin Stegenga; David R Freyer Journal: Semin Oncol Nurs Date: 2015-05-07 Impact factor: 2.315